Intracranial tumor implantation was performed on 8 week old post-natal NOD-SCID mice obtained from Jackson laboratory (stock #005557). Under isoflurane-induced anesthesia, 100,000 luciferase expressing human L1 GBM cells were injected in 1μL of culture media at coordinates X = 1.5mm, Y = 1.5mm and Z = 2.5mm relative to the bregma. Tumor formation was monitored by intraperitoneal injection of 3 mg/kg body weight of D-luciferin (Xenolight D-Luciferin firefly potassium salt, PerkinElmer, catalog# 122799) in sterile phosphate buffered saline (PBS) followed by IVIS imaging. Once photon counts reached between 2.5 and 7.0 × 107/sec, animals were divided into four groups with 10 mice per group and administered vehicle, saracatinib (25 mg/kg by oral gavage, 5 days per week), ispinesib (10 mg/kg by intraperitoneal injection for every 4 days) or ispinesib + saracatinib (10 mg/kg by intraperitoneal injection for every 4 days; 25 mg/kg by oral gavage, 5 days per week, respectively). IVIS imaging was performed every 4–8 days and photon flux was calculated from the resulting signal.
Xenolight d luciferin firefly potassium salt
Manufactured by PerkinElmer
Xenolight D-Luciferin firefly potassium salt is a bioluminescent substrate used in various in vitro and in vivo applications. It is the primary substrate for the firefly luciferase enzyme, which catalyzes a light-emitting reaction. The product is supplied as a purified salt formulation.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using xenolight d luciferin firefly potassium salt
1
Intracranial GBM mouse model for drug testing
2
Intracranial GBM mouse model for drug testing
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Intracranial tumor implantation was performed on 8 week old post-natal NOD-SCID mice obtained from Jackson laboratory (stock #005557). Under isoflurane-induced anesthesia, 100,000 luciferase expressing human L1 GBM cells were injected in 1μL of culture media at coordinates X = 1.5mm, Y = 1.5mm and Z = 2.5mm relative to the bregma. Tumor formation was monitored by intraperitoneal injection of 3 mg/kg body weight of D-luciferin (Xenolight D-Luciferin firefly potassium salt, PerkinElmer, catalog# 122799) in sterile phosphate buffered saline (PBS) followed by IVIS imaging. Once photon counts reached between 2.5 and 7.0 × 107/sec, animals were divided into four groups with 10 mice per group and administered vehicle, saracatinib (25 mg/kg by oral gavage, 5 days per week), ispinesib (10 mg/kg by intraperitoneal injection for every 4 days) or ispinesib + saracatinib (10 mg/kg by intraperitoneal injection for every 4 days; 25 mg/kg by oral gavage, 5 days per week, respectively). IVIS imaging was performed every 4–8 days and photon flux was calculated from the resulting signal.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!